Cyclacel Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.cyclacel.com
- Introduction
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Clinical Trials
18
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05817890
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT05358379
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT05168904
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT04983810
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04017546
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
Cyclacel's Plogosertib Shows Promise Against Biliary Tract Cancer in Preclinical Study
Independent researchers found that biliary tract cancer cell lines demonstrated sensitivity to plogosertib, a PLK1 inhibitor, both as monotherapy and in combination treatments.
Cyclacel Completes Enrollment in Fadraciclib Trial for Tumors with CDKN2A/B Abnormalities
Cyclacel Pharmaceuticals completed enrollment in Cohort 8 of its Phase 2 trial of fadraciclib, a CDK2/9 inhibitor, focusing on patients with advanced solid tumors and lymphoma exhibiting CDKN2A/B abnormalities.